好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of Interferon beta-1b and Glatiramer Acetate on New MTR Brain Lesions in MS
MS and Related Diseases
P07 - (-)
104
BACKGROUND: Analysis of the evolution of black holes in the BECOME study, a head to head trial of GA and IFN in which subjects randomized to either treatment underwent monthly MRI for 12 to 24 months, has been reported. Here we used MTR to identify new brain lesions and quantify their recovery during the BECOME study.
DESIGN/METHODS: T1-weighted images with and without a fat saturation pulse were acquired pre-treatment and monthly for 12-24 months after randomization. Experiments showed that percent difference fat saturation maps calculated from these images showed MTR contrast. Images were analyzed using a novel technique for measuring MTR changes over time. New MTR lesions were identified based on a drop in MTR signal that co-localized with a new T2 lesion, and MTR timecourses in that tissue before and after lesion formation were constructed. Differences in these timecourses due to the two treatments were modeled using a general linear random effects model.
RESULTS: Acute decrease in MTR associated with MTR lesion formation was followed by partial recovery to a stable level. This level was significantly greater in new MTR lesions from patients randomized to GA (p<0.0001). This difference was smaller, but still significant when the recovery of MTR was analyzed in new gadolinium-enhancing lesions detected using the highly sensitive triple-dose, delayed, 3T BECOME protocol.
CONCLUSIONS: We identified a novel type of lesion based on acute decreases in MTR, a marker of myelin density, and quantified the stable level to which MTR recovered in these lesions in BECOME study MS patients. Subjects randomized to GA showed significantly greater stable recovery levels of MTR, consistent with greater new MTR lesion repair and possibly remyelination.
Authors/Disclosures
Robert A. Brown, PhD (ShadowLab Reseaerch)
PRESENTER 		Dr. Brown has received stock or an ownership interest from ShadowLab Research Inc.. Dr. Brown has received intellectual property interests from a discovery or technology relating to health care. Dr. Brown has a non-compensated relationship as a consultant with the Population Council that is relevant to AAN interests or activities.
Stuart D. Cook, MD, FAAN (Rutgers) No disclosure on file
Diego Cadavid, MD, FAAN (Verge Genomics) Dr. Cadavid has received personal compensation for serving as an employee of Verge Genomics. Dr. Cadavid has received personal compensation for serving as an employee of Vertex Pharmaceuticals. Dr. Cadavid has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. Cadavid has or had stock in Verge Genomics.Dr. Cadavid has or had stock in Vertex Pharmaceuticals.
Irwin J. Kopin, MD No disclosure on file
Leo Wolansky, MD The institution of Dr. Wolansky has received research support from Guerbet.
Sridar Narayanan (Montreal Neurological Institute) Sridar Narayanan has received personal compensation for serving as an employee of NeuroRx Research. Sridar Narayanan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech Inc.. The institution of Sridar Narayanan has received research support from Immunotec Inc.
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.